abstract: AIM: To evaluate the relationship between human cytomegalovirus (HCMV) antibody status, and @entity101 and functional status among elderly Koreans. METHODS: @entity1 aged >= 65   years were prospectively enrolled from March 2011 to February 2012 at a 2000-bed university hospital. We collected data including @entity404 + and @entity405 + T-lymphocyte count, and functional status by measuring basic activities of daily living and instrumental activities of daily living for all @entity1 . In addition, HCMV immunoglobulin   G levels were analyzed using enzyme-linked fluorescent assay. RESULTS: During the study period, 103 @entity1 (51 @entity1 ), who were admitted for treatment of @entity281 or other diseases, were enrolled. Multivariate analysis showed that body mass index and HCMV immunoglobulin   G antibody titers were independent factors associated with @entity101 in elderly @entity1 (OR 1.347, 95% CI 1.113-1.630, P   =   0.002; OR 1.023, 95% CI 1.001-1.047, P   =   0.042, respectively). In univariate linear correlations, HCMV antibody levels were positively correlated with systolic blood pressure levels (r   =   0.303, P   =   0.002), @entity405 + T-lymphocyte count (r   =   0.313, P   =   0.001) and instrumental activities of daily living scores (r   =   0.217, P   =   0.028). In addition, HCMV immunoglobulin   G titers were inversely associated with estimated glomerular filtration rate (r   =   -0.268, P   =   0.006). These four variables remained independently significant in multivariate correlation analysis. CONCLUSION: These findings could provide insight into the important role of HCMV in the pathogenesis of essential @entity101 and decreased functional status in the elderly. Geriatr Gerontol Int 2014;       :       -      .

title: Association between human cytomegalovirus antibody levels, and essential XXXX and functional status in elderly Koreans.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'men']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']

answer: @entity101 :: (MESH:D006973,Disease) :: ['hypertension']


abstract: Eight-day pregnant Jcl:ICR @entity19 were administered @entity888 i.p. at doses of 11, 13, 14, 15, 17, 19 and 21 mg/kg. The number of animals that died after the treatment increased dose-dependently. The highest maternal mortality rate (50%) was observed in the 21 mg/kg group. On day 18 of gestation, the animals were killed and fetuses were examined for @entity853 . The mortality and @entity600 rates of fetuses increased with the increase in dose, but both rates reached their highest levels at a dose of 19 mg/kg. @entity601 , @entity3066 , @entity2419 and @entity154 were frequently observed @entity600 . The single teratogenic dose was estimated to be 19 mg/kg for both @entity853 . This amount was about ten times the daily intake of many Japanese abusers. The risk of malformed @entity1 being born to female abusers was considered to be high. More crowded conditions have been reported to increase the @entity2241 rate. The higher @entity600 rate in the 19 mg/kg group than in the 21 mg/kg group was considered to be due to fewer surviving @entity19 in the 21 mg/kg group, because of a higher mortality rate.

title: Teratogenic effects of @entity888 in XXXX .

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['rib anomaly']

entities_list: @entity888 :: ('MESH:D008694', 'Chemical') :: ['methamphetamine hydrochloride']

entities_list: @entity853 :: ('MESH:D009139', 'Disease') :: ['external and skeletal malformations']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['malformations', 'malformation']

entities_list: @entity601 :: ('MESH:D009436', 'Disease') :: ['Exencephaly']

entities_list: @entity3066 :: ('MESH:D005141', 'Disease') :: ['open eyelids']

entities_list: @entity2419 :: ('MESH:D002972', 'Disease') :: ['cleft palate']

entities_list: @entity2241 :: ('MESH:D005315', 'Disease') :: ['fetal malformation']

answer: @entity19 :: (10090,Species) :: ['mice']


abstract: The decision to perform protectomy must be considered very seriously in the course of @entity30 . The objectives of this study were to evaluate the consequences of this procedure: healing, @entity250 , quality of life and the subsequent course of the disease. From 1981 to 1993, we performed 24 proctectomies: 15 females, 9 males, mean age: 39 years (18-76), mean preoperating time: 9 +/- 4 years. @entity75 were always accompanied by pancolitis; ileal involvement was observed in 11 cases (45%) at the time of diagnosis of @entity30 , and in 4 cases at the time of proctectomy. Proctectomy was performed after a period of rectal exclusion in 19 @entity1 , while the rectum was not isolated for 5 others, including 2 @entity1 after total colectomy. The indication for surgery was based on the coexistence of a microrectum (n = 16), @entity850 (n = 15), @entity3622 (n = 15). Technical features were: close rectal dissection (n = 19), levator muscle preservation (n = 7), wall effraction (n = 8), primary closure (n = 6) or perineal wound packing (n = 8). Mean follow-up: 44 +/- 24 months, statistical analysis: Fisher's test, Wilcoxon's test and Kaplan-Meier method. No perioperative @entity204 were observed. An intraperitoneal collection required drainage. Mean hospital stay was 21 days. @entity458 were: @entity546 (n = 3), @entity177 (n = 1), not correlated to the type of dissection. Perineal wound healing was considered to be normal when it took less than 6 months (n = 14).(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Complications and course after proctectomy for XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['Rectal and anoperineal lesions']

entities_list: @entity458 :: ('MESH:D020018', 'Disease') :: ['Sexual complications']

entities_list: @entity3622 :: ('MESH:D012006', 'Disease') :: ['rectovaginal or complex fistulas']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['ejaculation failure']

entities_list: @entity546 :: ('MESH:D004414', 'Disease') :: ['dyspareunia']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['anal stenosis']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's disease"]

entities_list: @entity250 :: ('MESH:D012735', 'Disease') :: ['sexual disorders']

answer: @entity30 :: (MESH:D003424,Disease) :: ['Crohn disease']


abstract: AIM: To examine the effect of Weichang'an (WCA) and @entity1487 ( @entity1487 ) on @entity14 and hepatic @entity3 in a @entity19 model. METHODS: Quantitative determination of @entity35085 , the effective component in WCA decoction, was performed using HPLC. In vitro @entity137 of WCA was determined by treating HCT-116 cells with WCA diluents or serum extracted from @entity35 that received WCA by oral gavage for 1 wk and @entity98 assays. Forty-eight @entity19 received cecum implantation with @entity5 blocks subcutaneously amplified from @entity1 @entity694 cell line HCT-116. @entity19 were randomly divided into four treatment groups: control (CON), WCA, @entity1487 and combination (WCA+ @entity1487 ). Pathological examination of @entity5 consisted of tissue sectioning and @entity1710 and @entity1711 staining. @entity5 weight and size were measured, and the number of metastatic lesions was counted. Serum @entity6544 ( @entity6544 ) level was determined by ELISA. The expression levels of @entity5 genesis and @entity3 -related proteins b-catenin and @entity21423 were measured by real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR), immunohistochemistry and immunoblotting. Cell fractionation was used to investigate intracellular distribution of b-catenin. RESULTS: @entity5 were palpable in the abdomens of @entity19 2 wk post-implantation and orthotopic @entity5 formation rate was 100% in all groups. @entity1487 treatment alone significantly decreased @entity5 weight compared to the CON group (1.203  0.284 g vs 1.804  0.649 g, P<0.01). WCA treatment alone reduced the rate of @entity3 (50% vs 100%, P<0.05). Combination treatment of WCA+ @entity1487 was the most effective, reducing the @entity5 weight (1.140  0.464 g vs 1.804  0.649 g, P<0.01) and size (1493.438  740.906 mm3 vs 2180.259  816.556 mm3, P<0.05), the rate of @entity3 (40% vs 100%, P<0.01), and serum @entity6544 levels (31.263  7.421  g/L vs 43.040  11.273  g/L, P<0.05). Expression of b-catenin and @entity21423 was decreased in drug-treated groups compared to controls, as detected using real-time quantitative RT-PCR, immunohistochemistry and immunoblotting, respectively. Cell fractionation assays revealed that nuclear translocation of b-catenin was reduced by WCA and/or @entity1487 treatments. CONCLUSION: Combination of WCA with @entity1487 significantly inhibited @entity694 growth and hepatic @entity3 . Decreased expression of b-catenin and @entity21423 may be important.

title: Weichang'an and @entity1487 suppresses @entity14 in a XXXX model.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity']

entities_list: @entity19 :: ('10090', 'Species') :: ['Mice', 'mouse', 'nude mice']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Parenchymal tumors', 'Tumor', 'tumors']

entities_list: @entity6544 :: ('111518(Tax:10090)', 'Gene') :: ['CEA', 'carcinoembryonic antigen']

entities_list: @entity1710 :: ('MESH:D006416', 'Chemical') :: ['hematoxylin']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases', 'metastasis']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal tumor']

entities_list: @entity35085 :: ('MESH:D006569', 'Chemical') :: ['hesperidin']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colon cancer', 'colon tumor']

answer: @entity19 :: (10090,Species) :: ['mouse']


abstract: @entity57969 ( @entity57969 ) is a rare autosomal dominant genodermatosis with disturbed epidermal differentiation. Its clinical picture varies from transient, fast moving erythema to persistent @entity5656 . The gene defect in @entity57969 was recently located on the short arm of chromosome 1 encoding the gap junction protein @entity6360 . We report on a 48-year-old @entity1 with sharply circumscribed, scaling erythema on the extremities, buttocks and trunk starting since 30 years of age. Histological investigation showed @entity5656 with @entity8286 overlying an acanthotic epidermis. Immunohistochemistry revealed a decreased expression of the gap junction protein @entity6360 as well as increased expression of @entity495 . At the ultrastructural level, widened intercellular spaces in the @entity1729 were present with regular desmosomes, adherens junctions and gap junctions. Epidermal cell proliferation and differentiation are regulated by gap junctions. The mutation in @entity6360 is regarded therefore as causal for the clinical picture of the @entity57969 . The unique upregulation of @entity495 may occur as a consequence of the @entity6360 mutation and temporarily compensate for this defect.

title: [ XXXX ( @entity57969 )--a disorder due to altered epidermal expression of gap junction proteins].

entities_list: @entity5656 :: ('MESH:D017488', 'Disease') :: ['orthokeratotic hyperkeratosis', 'brown hyperkeratoses']

entities_list: @entity8286 :: ('MESH:D010241', 'Disease') :: ['focal parakeratosis']

entities_list: @entity1729 :: ('MESH:D012141', 'Disease') :: ['upper epidermis']

entities_list: @entity57969 :: ('MESH:D056266', 'Disease') :: ['EKV', 'Erythrokeratodermia variabilis']

answer: @entity57969 :: (MESH:D056266,Disease) :: ['Erythrokeratodermia variabilis']


abstract: @entity526 B/r was grown in chemostat cultures under various limitations with @entity413 as @entity505 source. Since @entity526 only synthesized the @entity413 dehydrogenase (GDH) apo-enzyme and not the appropriate cofactor, @entity31937 ( @entity31938 ), no @entity12742 production could be observed. However, when cell-saturating amounts of @entity31938 (nmol to mumol range) were pulsed into steady state @entity413 -excess cultures of @entity526 , the organisms responded with an instantaneous formation of @entity12742 and an increased @entity26 consumption rate. This showed that reconstitution of GDH in situ was possible. Hence, in order to examine the influence on @entity413 metabolism of an active GDH, @entity526 was grown aerobically in chemostat cultures under various limitations in the presence of @entity31938 . It was found that the presence of @entity31938 indeed had a sizable effect: at pH 5.5 under @entity1391 - or @entity597 -limited conditions more than 60% of the @entity413 consumed was converted to @entity12742 , which resulted in steady state @entity12742 concentrations up to 80 mmol/l. The specific rate of @entity12742 production (0.3-7.6 mmol.h-1.(g dry wt cells)-1) was dependent on the growth rate and the nature of the limitation. The production rate of other overflow metabolites such as @entity598 , @entity2388 , and @entity15706 , was only slightly altered in the presence of @entity31938 . The fact that the cells were now able to use an active GDH apparently did not affect apo-enzyme synthesis.

title: Quantitative aspects of @entity413 metabolism by @entity526 B/r, grown in the presence of XXXX .

entities_list: @entity15706 :: ('MESH:C029743', 'Chemical') :: ['2-oxoglutarate']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity597 :: ('CHEBI:16189', 'Chemical') :: ['sulphate']

entities_list: @entity598 :: ('CHEBI:47622', 'Chemical') :: ['acetate']

entities_list: @entity1391 :: ('CHEBI:26020', 'Chemical') :: ['phosphate']

entities_list: @entity12742 :: ('MESH:C030691', 'Chemical') :: ['gluconate']

entities_list: @entity2388 :: ('MESH:D019289', 'Chemical') :: ['pyruvate']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli', 'E. coli']

entities_list: @entity31937 :: ('MESH:D045542', 'Chemical') :: ['pyrroloquinoline quinone']

answer: @entity31937 :: (MESH:D045542,Chemical) :: ['pyrroloquinoline quinone']


abstract: @entity12196 -related outbreaks in @entity1573 and African guinea fowls are described. Four outbreaks were recorded in @entity1573 and one in guinea fowls. Periorbital swelling and @entity9849 were the consistently present clinical signs in all the diseased birds. In several, swollen hocks and wattles were also discerened. Birds which succumbed to the @entity281 showed petechiation in the internal organs and evidence of airsacculitis. @entity12196 was isolated from the lesions and also from conjunctival swabs of the apparently healthy in-contact birds. There was no evidence of concurrent @entity281 with @entity6728 , @entity9463 or @entity1047 . @entity1536 therapy when resorted to on one of the farms resolved the clinical signs. Phenotypes of 28 isolates were studied. The results compared well with the @entity12196 isolates reported earlier from elsewhere. It was also found that results of @entity6122 fermentation and ONPG test appear to be a variable character. There is no earlier report of P. @entity281 in guinea fowls.

title: XXXX : Zimbabwean experience of a versatile pathogen.

entities_list: @entity9463 :: ('MESH:D009175', 'Disease') :: ['Mycoplasma']

entities_list: @entity9849 :: ('MESH:D007637', 'Disease') :: ['keratoconjunctivitis']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['gallinarum infection', 'infection']

entities_list: @entity6728 :: ('MESH:D006192', 'Disease') :: ['Haemophilus']

entities_list: @entity12196 :: ('MESH:D010326', 'Disease') :: ['Pasteurella gallinarum']

entities_list: @entity1047 :: ('MESH:D002690', 'Disease') :: ['Chlamydia']

entities_list: @entity1536 :: ('CHEBI:23765', 'Chemical') :: ['Quinolone']

answer: @entity12196 :: (MESH:D010326,Disease) :: ['Pasteurella gallinarum']


abstract: Between November 7, 1988 and December 31, 1989, 881 treatments were given with the @entity20096 9000 lithotriptor to 513 sites in 510 renal units in 464 @entity1 . Of the stones 447 (87.1%) were in the kidney, 64 (12.5%) in the ureter and 2 (0.4%) in the bladder. Stone size was up to 2 cm. in 58.5% of the cases, greater than 2 to 3 cm. in 25.8% and more than 3 cm. in 15.7%, including complete or partial staghorn, or multiple stones. Of the @entity1 54.2% received only 1 treatment, 17.6% received 2 treatments and 28.2% received more than 2 treatments (re-treatment was necessary in 45.8%). The number of shocks used varied from 610 to 4,000 at 14 to 24 kv., the usual energy used being 18 kv. Of the stones 30.2% were treated after Double-J stents were inserted. A @entity1 was declared stone-free only when no stone particle was visible on a plain abdominal x-ray (or ultrasound if the stone was radiolucent). X-rays 3 months after extracorporeal shock wave lithotripsy (ESWL) were available for review in 397 @entity1 (79.9%) and 72.8% were stone-free (with the aforementioned criteria) at 6 months (61.5% without ancillary procedures and 11.3% after ancillary procedures). Of a subset of 106 @entity1 84% were stone-free within 3 months when ESWL was restricted to a smaller stone burden, the number of shock waves administered was increased and energy was restricted to 14 to 18 kv. Over-all, 9.1% of the @entity1 needed ancillary measures, including percutaneous nephrostomy in 1.6%, push-back for ESWL in 1.9%, ureterorenoscopy in 5.4%, percutaneous nephrolithotomy in 0.6% and pyelolithotomy/ureterolithotomy in 2.8%. The @entity20096 9000 device has the unique combination of electrohydraulic shock wave generation and ultrasound monitoring. The latter attribute has the distinct advantage of avoiding radiation to allow for visualization of nonopaque renal and gallbladder calculi. In addition, because there is continuous stone visualization during fragmentation accurate stone targeting can be maintained. The combination of ultrasound monitoring and spark gap technology allows for effective stone fragmentation.

title: Extracorporeal shock wave lithotripsy for urinary tract stones using XXXX 9000 spark gap technology and ultrasound monitoring.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

answer: @entity20096 :: (4352,Gene) :: ['MPL']


abstract: BACKGROUND: @entity3052 ( @entity3052 ) accounts for 25%-35% of @entity3052 in @entity1 . @entity48704 gene (Brain and @entity3052 Cytoplasmic gene) is a recently identified gene on chromosome 8q22.3 that has prognostic significance in @entity3052 . The aim of this work was to study the impact of @entity48704 gene expression on prognosis of @entity3052 in Egyptian @entity1 . @entity1 AND METHODS: This study was conducted on 40 Egyptian @entity1 with newly diagnosed @entity3052 who were subjected to full history taking, clinical examination and laboratory investigations including: complete blood count, LDH, @entity236 , cytochemistry, immunophenotyping and assessment of @entity48704 Gene by real time PCR in bone marrow aspirate mononuclear cells before the start of chemotherapy. RESULTS: Positive @entity48704 gene expression was found in 24 cases (60%) and negative expression in 16 cases (40%). Positive @entity48704 gene expression group includes 14 males and 10 females with mean age at presentation of 8.35  2.63 while negative @entity48704 gene expression includes 10 males and 6 females with mean age at presentation of 7.74  3.23 with no statistically significant differences between @entity1 with positive and negative @entity48704 gene expression regarding age, sex and clinical presentations at time of diagnosis including pallor, @entity4125 , @entity381 , @entity382 and @entity3329 and laboratory investigations including WBCs and platelets counts, hemoglobin and LDH levels, and peripheral blood and bone marrow blast cell counts. There was significant association between positive @entity48704 gene expression and M1 and M2 compared with negative @entity48704 gene expression which is significantly associated with M4. There were statistically significant differences in disease outcome between positive and negative @entity48704 gene expression groups with higher rate of relapse and @entity204 and lower rate of complete remission and disease free survival in positive @entity48704 gene expression group compared with negative @entity48704 gene expression group. (p = 0.017). CONCLUSION AND RECOMMENDATION: @entity48704 expression is an important bad prognostic factor in @entity3052 @entity1 with normal karyotype and therefore we recommend its incorporation into novel risk-adapted therapeutic strategies to improve the currently disappointing cure rate of @entity1 with @entity3052 .

title: Prognostic value of brain and @entity3052 cytoplasmic gene expression in egyptian XXXX with @entity3052 .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'PATIENTS']

entities_list: @entity3329 :: ('MESH:D008206', 'Disease') :: ['lymphadenopathy']

entities_list: @entity3052 :: ('MESH:D015470', 'Disease') :: ['Acute Leukemia', 'Acute myeloid leukemia', 'AML', 'acute leukemia']

entities_list: @entity381 :: ('MESH:D013163', 'Disease') :: ['splenomegaly']

entities_list: @entity382 :: ('MESH:D006529', 'Disease') :: ['hepatomegaly']

entities_list: @entity236 :: ('MESH:D001855', 'Disease') :: ['bone marrow aspiration']

answer: @entity1 :: (9606,Species) :: ['children']


abstract: BACKGROUND: The aim of this dose-finding study was to evaluate the dose-response relationship of @entity19271 and @entity1339 to reverse a commonly observed level of incomplete recovery from @entity2898 -induced @entity4094 , that is, a train-of-four ratio (TOFR) >= 0.2. METHODS: Ninety-nine anaesthetized @entity1 received @entity2898 0.6 mg kg(-1) i.v. for tracheal intubation and, if necessary, incremental doses of 0.1-0.2 mg kg(-1). Neuromuscular monitoring was performed by calibrated electromyography. Once the TOFR recovered to 0.2, @entity1 were randomized to receive @entity19271 (0.25, 0.5, 0.75, 1.0, or 1.25 mg kg(-1) i.v.), @entity1339 (10, 25, 40, 55, or 70   g kg(-1) i.v.), or saline (n=9 per group). Primary and secondary end points were the doses necessary to restore neuromuscular function to a TOFR>= 0.9 with an upper limit of 5 and 10 min for 95% of @entity1 , respectively. RESULTS: @entity1339 was not able to fulfil the end points. Based on the best-fitting model, the @entity19271 dose estimation for recovery to a TOFR>= 0.9 for 95% of @entity1 within 5 and 10 min was 0.49 and 0.26 mg kg(-1), respectively. CONCLUSION: A residual @entity4094 of a TOFR of 0.2 cannot be reversed reliably with @entity1339 within 10 min. In the conditions studied, substantially lower doses of @entity19271 than the approved dose of 2.0 mg kg(-1) may be sufficient to reverse residual @entity2898 -induced @entity4094 at a recovery of TOFR>= 0.2. CLINICAL TRIAL REGISTRATION: NCT01006720.

title: XXXX and @entity1339 dose-finding study for reversal of residual @entity4094 at a train-of-four ratio of 0.2 (SUNDRO20)   ,.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity4094 :: ('MESH:D009468', 'Disease') :: ['neuromuscular block']

entities_list: @entity2898 :: ('MESH:C061870', 'Chemical') :: ['rocuronium']

entities_list: @entity1339 :: ('MESH:D009388', 'Chemical') :: ['neostigmine', 'Neostigmine']

entities_list: @entity19271 :: ('MESH:C453980', 'Chemical') :: ['sugammadex']

answer: @entity19271 :: (MESH:C453980,Chemical) :: ['Sugammadex']


abstract: UNASSIGNED: Inflammation is a protective response that is implicated in @entity2348 and other @entity9963 . The inflammatory mechanisms behind @entity1678 infections in fish remain poorly understood. In this study, we performed a de novo @entity26584 transcriptome assembly using Illumina's Solexa sequencing technique. On this basis we carried out a comparative analysis of intestinal transcriptomes from A. hydrophila-challenged and physiological saline solution (PSS/mock) -challenged fish, and 315 genes were up-regulated and 234 were down-regulated in the intestines infected with A. hydrophila. The GO enrichment analysis indicated that the differentially expressed genes were enriched to 12, 4, and 8 GO terms in biological process, molecular function, and cellular component, respectively. A KEGG analysis showed that 549 DEGs were involved in 165 pathways. Moreover, 15 DEGs were selected for quantitative real-time PCR analysis to validate the RNA-seq data. The results confirmed the consistency of the expression levels between RNA-seq and qPCR data. In addition, a time-course analysis of the mRNA expression of 12 inflammatory genes further demonstrated that the intestinal inflammatory responses to A. hydrophila infection simultaneously modulated gene expression variations. The present study provides intestine-specific transcriptome data, allowing us to unravel the mechanisms of intestinal @entity32 triggered by bacterial pathogens.

title: A transcriptome analysis focusing on @entity32 -related genes of @entity26584 intestines following infection with XXXX .

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity9963 :: ('MESH:D005393', 'Disease') :: ['fish diseases']

entities_list: @entity2348 :: ('MESH:D001424', 'Disease') :: ['bacterial enteritis']

entities_list: @entity1678 :: ('644', 'Species') :: ['Aeromonas hydrophila']

answer: @entity1678 :: (644,Species) :: ['Aeromonas hydrophila']


abstract: UNASSIGNED: @entity3392 embryos are being increasingly used as model organisms for the assessment of single substances and complex environmental samples for regulatory purposes. Thus, it is essential to fully understand the xenobiotic metabolism during the different life-stages of early development. The aim of the present study was to determine arylhydrocarbon receptor (AhR)-mediated activity during selected times of early development using qPCR, enzymatic activity through measurement of 7-ethoxyresorufin-O-deethylase (EROD) activity, and protein expression analysis. In the present study, gene expression of @entity44609 , @entity58957 , @entity58958 , @entity58959 , and @entity58960 as well as EROD activity were investigated up to 120  h postfertilization (hpf) after exposure to either b-naphthoflavone (BNF) or a polycyclic aromatic hydrocarbons (PAH)-contaminated sediment extract from Vering Kanal in Hamburg (VK). Protein expression was measured at 72  hpf after exposure to 20   g/L BNF. Altered proteins were identified by matrix assisted laser desorption ionization time-of-flight (MALDI-TOF) peptide mass fingerprinting. Distinct patterns of basal messenger RNA (mRNA) expression were found for each of the @entity58961 genes, suggesting specific roles during embryonic development. All transcripts were induced by BNF and VK. @entity58960 mRNA expression was significantly upregulated after exposure to VK. All @entity58961 genes investigated showed a temporal decline in expression at 72  hpf. The significant decline of @entity10378 protein at 72  hpf after exposure to BNF may suggest an explanation for the decline of @entity58961 genes at this time point as @entity10378 is of major importance for the functioning of the Ah-receptor. EROD activity measured in embryos was significantly induced after 96  hpf of exposure to BNF or VK. Together, these results demonstrate distinct temporal patterns of @entity58961 genes and protein activities in @entity3392 embryos as well as show a need to investigate further the xenobiotic biotransformation system during early development of @entity3392 .

title: Time-dependent expression and activity of cytochrome P450 1s in early life-stages of the XXXX ( @entity3392 ).

entities_list: @entity3392 :: ('7955', 'Species') :: ['Zebrafish', 'zebrafish']

answer: @entity3392 :: (7955,Species) :: ['zebrafish']


abstract: @entity6961 (EMS) is a rare disease characterized by @entity5 ( @entity5 ) associated with @entity1712 and T or @entity981 / @entity1778 . EMS is defined by molecular disruption of the @entity7167 gene at the 8p11-12 chromosome locus, and various partner genes are associated with @entity7167 gene translocation or insertion. The different partner- @entity7167 fusion genes are associated with slightly different disease phenotypes. The present @entity1 showed @entity981 in a cervical lymph node, involvement of @entity706 in the skin, and @entity5 bone marrow morphology with @entity1897 . Chromosome analysis of the @entity1 showed t(1;8)(q25; @entity1354 .2). To our knowledge, only 2 cases of EMS with translocation of t(1;8)(q25; @entity1354 .2) have been previously reported. Including this case, all 3 cases with EMS with t(1;8)(q25; @entity1354 .2) showed @entity5 bone marrow morphology and @entity1897 . These findings support that t(1;8)(q25; @entity1354 .2) is associated with @entity1897 in EMS @entity1 . Of the 2 cases of EMS with t(1;8)(q25; @entity1354 .2) which were previously reported, @entity7167 rearrangement was not confirmed in 1 case. Similarly, @entity7167 rearrangement in the present case was not detected by fluorescence in situ hybridization or reverse transcription-polymerase chain reaction. Further study is needed to identify other techniques that could be used to demonstrate @entity7167 rearrangement.    2014 S. Karger AG, Basel.

title: 8 @entity1354 Myeloproliferative Syndrome with t(1;8)(q25; XXXX .2): A Case Report and Review of the Literature.

entities_list: @entity1712 :: ('MESH:D004802', 'Disease') :: ['eosinophilia']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity981 :: ('MESH:D054198', 'Disease') :: ['T lymphoblastic lymphoma', 'B lymphoblastic lymphoma']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['malignant lymphoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['myeloproliferative neoplasm', 'MPN']

entities_list: @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral monocytosis']

entities_list: @entity6961 :: ('MESH:D009196', 'Disease') :: ['8p11 myeloproliferative syndrome']

answer: @entity1354 :: (8909,Gene) :: ['p11']


abstract: BACKGROUND: @entity1229 is commonly used as a secondary prevention of @entity64 in @entity1 with @entity955 ( @entity955 ). However, limitations have been observed even with the use of this medication. Recently, several newer direct oral anticoagulants (DOACs) have been approved for use by the food and drug administrations. Unfortunately, these newer drugs have seldom been compared directly with each other. Therefore, this study aimed to compare the @entity548 events associated with @entity3925 and @entity3926 in @entity1 treated for @entity955 . METHODS: EMBASE, Medline (National Library of Medicine) and the Cochrane Central Registry of Controlled Trials were searched for studies comparing @entity3925 with @entity3926 using the terms ' @entity3925 , @entity3926 and @entity955 '. Primary endpoints were: any @entity548 outcomes, @entity548 . Secondary outcomes included @entity64 ( @entity64 )/transient @entity63 and mortality. Odds ratios (OR) with 95% confidence intervals (CIs) were calculated. The pooled analyses were carried out with RevMan 5.3 software. All the authors had full access to the data and approved the manuscript as written. RESULTS: A total number of 4895 @entity1 were included. This analysis showed that @entity3925 was not associated with a significantly higher @entity548 event when compared to @entity3926 (OR: 1.28, 95% CI: 0.95-1.72; P   =   0.11). @entity548 was similarly manifested between these two DOACs (OR: 0.98, 95% CI: 0.43-2.25; P   =   0.97). Even if @entity510 was higher with the use of @entity3925 , (OR: 2.18, 95% CI: 0.51-9.25; P   =   0.29), the result was not statistically significant. Moreover, @entity64 were also not significantly different (OR: 0.81, 95% CI: 0.53-1.23; P   =   0.32) and (OR: 2.06, 95% CI: 0.73-5.82; P   =   0.17) respectively. However, even if mortality favored @entity3926 (OR: 1.42, 95% CI: 0.99-2.06; P   =   0.06), this result only approached statistical significance. CONCLUSION: Head to head comparison showed that @entity3925 was not associated with significantly higher @entity548 events compared to @entity3926 . @entity510 , @entity548 , @entity64 and mortality were also not significantly different between these two DOACs. However, due to the limited number of @entity1 analyzed, and which were mainly obtained from observational studies, this hypothesis might only be confirmed in future randomized trials. Furthermore, the CHADS2-VASC and HAS-BLED score which might play an important role in predicting @entity548 risks should also not be ignored.

title: Bleeding outcomes associated with @entity3925 and @entity3926 in @entity1 treated for XXXX : a systematic review and meta-analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['SE', 'stroke/SE/TIA, venous thromboembolism', 'stroke/SE/TIA and venous thromboembolism', 'stroke/systemic embolism', 'stroke']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['GI bleeding', 'bleeding', 'intracranial bleeding and gastro-intestinal (GI) bleeding']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic attack (TIA), venous thromboembolism']

entities_list: @entity510 :: ('MESH:D013345', 'Disease') :: ['intracranial bleeding', 'Intracranial bleeding']

entities_list: @entity3926 :: ('MESH:C554682', 'Chemical') :: ['dabigatran']

entities_list: @entity3925 :: ('MESH:C503223', 'Chemical') :: ['rivaroxaban']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation', 'AF', 'non-valvular AF']

entities_list: @entity1229 :: ('MESH:D014859', 'Chemical') :: ['Warfarin']

answer: @entity955 :: (MESH:D001281,Disease) :: ['atrial fibrillation']


abstract: INTRODUCTION: Non- @entity2067 antagonist oral anticoagulants (NOACs) have been developed to prevent @entity385 and systemic @entity1031 in @entity1 with nonvalvular @entity955 . Owing to their predictable pharmacological profiles, they can be given in fixed doses without the need for routine coagulation monitoring. However, their distinctive pharmacological properties also raise issues about potential drug interactions. AREAS COVERED: A literature search was conducted to extract published studies on the pharmacodynamics and drug interactions involving NOACs. Available data from US FDA and European Medicine Agency were also included. As these agents are substrates of permeability glycoprotein (P-gp) efflux transporter and/or @entity5322 enzymes, articles focusing on the co-administration of NOACs and drugs affecting these pathways are discussed. Concomitant use of NOACs with antiplatelet agents may potentially increase @entity548 risk. EXPERT OPINION: Measurement of anticoagulant effects is desired to evaluate the risk of @entity1031 or @entity548 for @entity1 with NOACs. Prescribers should be vigilant against combination prescription of NOACs with strong inhibitors (such as @entity3102 ) or inducers of P-gp and/or @entity5322 (such as @entity1215 ). Potential benefit of concurrent use of these agents with antiplatelet drugs should be cautiously balanced against latent risk in specific clinical situations.

title: Pharmacodynamic profile and drug interactions with non- @entity2067 antagonist oral anticoagulants: implications for XXXX with @entity955 .

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity2067 :: ('MESH:D014812', 'Chemical') :: ['vitamin K']

entities_list: @entity3102 :: ('MESH:D007654', 'Chemical') :: ['ketoconazole']

entities_list: @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolism']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation']

entities_list: @entity1215 :: ('MESH:D012293', 'Chemical') :: ['rifampicin']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: @entity2316 is a multifactorial @entity6 complication whose long-term consequences involve @entity740 and increased rate of @entity65 . Besides oxidative stress, and hemodynamic changes, glycosaminoglycans (GAGs) are an additional component implicated in the onset of @entity8 . GAG replacement therapy was envisaged in the nineties for the treatment of @entity2316 and @entity40204 is the most extensively investigated GAG to reduce @entity633 in @entity6 @entity1 . METHODS: In this study we have evaluated the effect of a long-term course of oral @entity40204 at a moderate dosage in the treatment of @entity1 affected by @entity2316 . Thirty @entity1 with type 1 and 2 @entity6 ( @entity6 ) have been treated with 50 mg/ daily oral @entity40204 for 12 months while thirty matched @entity6 @entity1 constituted the control group. All the @entity1 attended monthly visits and controls of biochemical and metabolic parameters. RESULTS: At 12 months @entity633 was greatly reduced in @entity1 treated with @entity40204 and increased in the control group (260% and +29% vs baseline, respectively; p = 0.0001). The drug appeared active in both type 1 and type 2 @entity6 and in both micro- and macroalbuminuric @entity1 . No change in metabolic control and no systemic side effects were reported. CONCLUSIONS: In our @entity6 @entity1 @entity40204 therapy has been proven to greatly reduce @entity633 , and to have the potential to delay progression from incipient to overt @entity8 .

title: One year course of oral @entity40204 in the management of XXXX .

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['nephropathy', 'glomerular abnormalities']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes', 'diabetes mellitus', 'DM']

entities_list: @entity2316 :: ('MESH:D003928', 'Disease') :: ['diabetic nephropathy', 'Diabetic nephropathy']

entities_list: @entity740 :: ('MESH:D051436', 'Disease') :: ['chronic renal insufficiency']

entities_list: @entity633 :: ('MESH:D000419', 'Disease') :: ['albuminuria']

entities_list: @entity40204 :: ('MESH:C007858', 'Chemical') :: ['sulodexide']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular death']

answer: @entity2316 :: (MESH:D003928,Disease) :: ['diabetic nephropathy']


abstract: @entity1 with @entity1002 ( @entity1002 ) are at increased risk for dying suddenly of cardiac causes. The most common causes of @entity1002 are @entity453 ( @entity453 ) and @entity583 ( @entity583 ). Aggressive intervention following @entity583 is essential for minimizing the @entity296 that leads to @entity1002 and the subsequent risk for @entity712 and @entity1164 . This article describes practical algorithms for managing the @entity1 post @entity583 to minimize such risks. The degree of @entity1002 is a key factor for determining clinical management strategies in the @entity1 post @entity583 . Risk factor reduction and selective neurohormonal blockade, especially with angiotensin-converting enzyme inhibitors, are usually recommended in the presence or absence of @entity1002 , along with early use of a beta blocker. In @entity1 with @entity1002 , more aggressive intervention includes extended use of a beta blocker. In cases of @entity1002 progressed to @entity712 , the mixed beta and alpha blocker @entity1405 has improved outcomes significantly. In clinical trials, @entity1405 has been demonstrated to have antiarrhythmic activity, a property that offers protection against @entity944 in high-risk @entity1 with @entity1002 . Addition of an @entity1369 antagonist is also advised in @entity1 with @entity712 . In selected @entity1 with reduced ejection fractions, use of surgical/catheter treatment and device therapy offers further benefits.

title: Real-world algorithms for the optimal use of drugs and devices in the @entity1 post @entity583 and the future of post XXXX management.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity1164 :: ('MESH:D016757', 'Disease') :: ['sudden cardiac death']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial damage']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'MI']

entities_list: @entity1369 :: ('MESH:D000450', 'Chemical') :: ['aldosterone']

entities_list: @entity944 :: ('MESH:D003645', 'Disease') :: ['sudden arrhythmic death']

entities_list: @entity1405 :: ('MESH:C043211', 'Chemical') :: ['carvedilol']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['CAD', 'coronary artery disease']

entities_list: @entity1002 :: ('MESH:D018487', 'Disease') :: ['LVD', 'left ventricular dysfunction']

answer: @entity583 :: (MESH:D009203,Disease) :: ['myocardial infarction']


abstract: BACKGROUND: @entity3178 , including @entity4143 and @entity11162 , mainly affects middle aged and older subjects, with a female predominance in @entity4143 . The diseases have previously been regarded as rare. We present an epidemiological study of @entity3178 in a well defined Swedish population. METHODS: @entity1 were retrospectively searched for in colonoscopy reports of those who had a colonoscopy in the period 1993-1998 for non-bloody @entity294 . All @entity1049 were reassessed using strict diagnostic criteria. RESULTS: Biopsies from 1018 @entity1 were reassessed. Fifty one (45 female) @entity4143 @entity1 and 46 (31 female) @entity11162 @entity1 were diagnosed. Median age at diagnosis was 64 years in @entity4143 and 59 years in @entity11162 . The mean annual incidence of @entity4143 was 4.9/10(5) inhabitants (95% confidence interval (CI) 3.6-6.2/10(5)) and of @entity11162 4.4/10(5) inhabitants (95% CI 3.1-5.7/10(5)). The annual incidence of @entity4143 increased from 3.7/10(5) in 1993-1995 to 6.1/10(5) in 1996-1998 (difference 2.4/10(5) (95% CI -0.3-5.1/10(5))) whereas the incidence of @entity11162 increased from 3.1/10(5) to 5.7/10(5) (difference 2.6/10(5) (95% CI 0.1-5.2/10(5))). CONCLUSIONS: The annual incidences of @entity4143 and @entity11162 are higher than considered previously and are now equal to the incidence of @entity30 in Sweden, and combined rates approach the incidence of @entity31 . @entity3178 was diagnosed in 10% of all @entity1 with non-bloody @entity294 referred for colonoscopy and in almost 20% of those older than 70 years.

title: XXXX : a common diarrhoeal disease. An epidemiological study in Orebro, Sweden, 1993-1998.

entities_list: @entity11162 :: ('MESH:D046730', 'Disease') :: ['lymphocytic colitis']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhoea']

entities_list: @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis']

entities_list: @entity3178 :: ('MESH:D046728', 'Disease') :: ['Microscopic colitis', 'microscopic colitis']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's disease"]

entities_list: @entity4143 :: ('MESH:D046729', 'Disease') :: ['collagenous colitis']

entities_list: @entity1049 :: ('MESH:D003108', 'Disease') :: ['colonic mucosal biopsies']

answer: @entity3178 :: (MESH:D046728,Disease) :: ['Microscopic colitis']


abstract: Beta (b)- @entity2395 is the most frequently observed @entity74 in the world. It is characterized by deficiency of hemoglobin b-globin gene and is also a profoundly heterogeneous both at the molecular and clinical level. In the case of @entity8674 , there is reduced (b(+) type) or absent (b(o) type) synthesis of the  beta chains of  hemoglobin. @entity8674 clinically occurs in three main forms: major, intermedia and minor according to requirement of transfusion. The objective of this study was to evaluate @entity8674 mutations in 89 @entity1 ranging from 2  months  to 16  years of age, who enrolled to Medical School Research and Training Hospital, Gaziantep University. The direct DNA sequence analysis was performed for mutation scanning of b-globin gene. 89 @entity1 with @entity8674 including all types were analyzed, 16 different @entity8674 mutations were detected. We have also identified a novel mutation (HBB. @entity59391 , @entity59392 ) in the promoter region (-30 TATA box) of b-globin gene, and clinical data of @entity1 having novel mutation was given. The @entity8674 mutations were determined as @entity8674 major type in 42 @entity1 (47.19  %), @entity8674 intermedia in 4 (4.49  %), @entity8674 minor in 43, (48.31  %) @entity1 . The most frequent mutation was IVS @entity59393 , followed by IVS @entity59394 , IVS @entity59395 , @entity40977 , respectively.

title: Novel   eta (b)- @entity2395 Mutation in Turkish XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient']

entities_list: @entity59394 :: ('c|SUB|I,G|-1|A', 'ProteinMutation') :: ['I-1 G>A']

entities_list: @entity59395 :: ('c|SUB|I,T|-6|C', 'ProteinMutation') :: ['I-6 T>C']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['hereditary blood disorder']

entities_list: @entity8674 :: ('MESH:D017086', 'Disease') :: ['b-thalassemia', 'b-Thalassemia']

entities_list: @entity40977 :: ('c|SUB|G|IVSII-1|A', 'DNAMutation') :: ['IVS II-1 G>A']

entities_list: @entity2395 :: ('MESH:D013789', 'Disease') :: ['thalassemia']

answer: @entity1 :: (9606,Species) :: ['Children']


abstract: BACKGROUND: @entity1643 is one of the four most common diseases in the world with great socioeconomic impact. Supervised exercise therapy is one of the treatments suggested for this condition; however, the recommendation on the best type of exercise is still unclear. The Pilates method of exercise is effective in reducing @entity158 and disability in these @entity1 , as well as the analgesia promoted by interferential current. Currently, the literature lacks information on the efficacy of the association of these two techniques in the short- and medium-term than performing one of the techniques isolated. The objective of this study will be to evaluate the efficacy of adding interferential current to the Pilates method exercises for the treatment of @entity1 with chronic nonspecific @entity1643 in the short- and medium-term. METHODS/DESIGN: This study will be a randomized controlled trial with two arms and blinded evaluator, conducted at an outpatient Physical Therapy Department in Brazil. @entity1 with nonspecific @entity1643 and @entity158 equal to or greater than 3 in the Pain Numerical Rating Scale (0/10) will be randomly assigned to one of two groups: Group with active interferential current   +   Pilates (n   =   74) will be submitted to the active interferential current associated to the modified Pilates exercises, and Group with sham interferential current   +   Pilates (n   =   74) will be submitted to the sham interferential current associated with the modified Pilates exercises during 18 sessions. The outcomes @entity158 intensity, pressure @entity158 threshold, general and specific disability, global perceived effect and kinesiophobia will be evaluated by a blinded assessor at baseline, six weeks and six months after randomization. DISCUSSION: Because of the study design, blinding of the @entity1 and the therapists involved in the study will not be possible. The results of this study could contribute to the process of clinical decision- making for the improvement of @entity158 and disability in @entity1 with nonspecific @entity1643 . TRIAL REGISTRATION: ClinicalTrials.gov NCT01919268.

title: Efficacy of the addition of interferential current to Pilates method in XXXX with @entity1643 : a protocol of a randomized controlled trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Patients', 'patients']

entities_list: @entity1643 :: ('MESH:D017116', 'Disease') :: ['chronic low back pain', 'Chronic low back pain', 'low back pain']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: It is estimated that approximately 10 to 15 million Americans have @entity438 . @entity438 are classified as either unruptured or ruptured. Advances in knowledge and technology are enhancing diagnosis, management, and outcomes associated with unruptured @entity438 . Optimal outcomes are achieved when @entity439 are treated before they @entity397 . If the @entity1756 , the mortality rate ranges from 30% to 60%. A review of evidence regarding @entity439 , including the pathogenesis, risk factors, treatment options, and outcomes, is presented. Treatment options addressed include surgical clipping, endovascular coiling, or watchful waiting. Current evidence supports aggressive treatment for @entity1 with previously @entity1756 , large or symptomatic @entity439 , a family history of @entity1756 , a long life expectancy, and @entity439 demonstrating growth. Factors that favor watchful waiting include @entity439 that are small or located in the anterior circulation and in @entity1 with a short life expectancy or comorbid medical conditions. Nurses are in an ideal position to use evidence and outcomes to provide accurate and current information on how to reduce the risks for @entity397 and evaluate treatment options.

title: Unruptured @entity438 : using evidence and outcomes to guide XXXX teaching.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity438 :: ('MESH:D002532', 'Disease') :: ['intracranial aneurysms', 'Intracranial aneurysms']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysms']

entities_list: @entity1756 :: ('MESH:D017542', 'Disease') :: ['ruptured aneurysms', 'aneurysm ruptures', 'aneurysm rupture']

answer: @entity1 :: (9606,Species) :: ['patient']


abstract: BACKGROUND: When an infection is suspected in a @entity1 with @entity5 and a central venous line (CVL), cultures are often only obtained from the CVL and not from a peripheral vein (PV). This study was undertaken to evaluate the importance of concomitant blood cultures from the CVL and a PV. PROCEDURE: Clinical data and the results of all cultures taken concomitantly from the CVL and a PV were registered prospectively in @entity1 admitted with @entity221 from April 2008 to December 2012 at the Department of Pediatrics at Aarhus University Hospital Skejby. RESULTS: During the study period 654 paired cultures obtained from the CVL and from a PV within two hour of each other were included. A true @entity281 ( @entity281 ) was registered in 112 episodes. In 20 (17%) out of 112, true @entity281 growth of a microorganism was detected only in the culture from a PV including seven cases of @entity526 and three cases of @entity794 . In 52 episodes the same microorganism was cultured from both the CVL and a PV. Twenty-four of these episodes were classified as catheter-related bloodstream infections (CRBSI) using differential time to positivity. In total, 64 (57%) of all true @entity281 were defined as CRBSI. CONCLUSIONS: Blood cultures should be obtained from a PV in addition to cultures from CVL at the onset of @entity221 in pediatric @entity1 with @entity5 in order to maximize the findings of true BSIs. The frequency of CRBSI may be over-estimated if blood cultures are drawn from CVL only. Pediatr @entity5    2014 Wiley Periodicals, Inc.

title: Importance of blood cultures from peripheral veins in pediatric @entity1 with XXXX and a central venous line.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'child']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Blood Cancer', 'cancer']

entities_list: @entity794 :: ('1280', 'Species') :: ['Staphylococcus aureus']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['bloodstream infection', 'BSI']

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: BACKGROUND: It has been proposed that @entity320 progression involves a multistep process from benign nevi (BN), @entity6349 ( @entity6349 ), radial and vertical growth phase @entity320 ( @entity320 ) to @entity320 ( @entity320 ). Protein @entity669 kinases (PTKs) may participate in this progression. METHODS: Tissue microarray blocks of 89 @entity75 were evaluated by immunohistochemistry for the expression of selected PTKs: @entity2467 , @entity1861 , abl-related gene ( @entity534 ), platelet-derived growth factor receptors alpha ( @entity18514 ( @entity3820 ). RESULTS: Seventeen of 31 (55%) @entity320 lacked expression of @entity2467 versus 100% expression (18/18) in @entity6349 and 96% expression (22/23) in @entity320 ; similarly, only 59% (10/17) of BN showed expression of @entity2467 . @entity3820 expression levels were similar in BN, @entity6349 , and @entity320 , but lower in @entity320 . There was a trend toward lower expression of abl and @entity534 from BN to @entity320 . There was a marked decrease in staining intensity of @entity534 from BN to @entity6349 , @entity320 , and @entity320 . CONCLUSION: Our results support that BN is different from @entity6349 and @entity320 and that these two are different from @entity320 . @entity3 appears to be associated with loss of @entity2467 and @entity3820 expression. Since malignant @entity320 expresses PTK, it may be a candidate for treatment with anti-PTK, such as @entity2213 (Gleevec).

title: Analysis of protein @entity669 kinase expression in XXXX by tissue array.

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'MM', 'metastatic melanoma', 'MMM']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['melanocytic lesions']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['Metastasis']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

entities_list: @entity6349 :: ('MESH:D004416', 'Disease') :: ['DN', 'dysplastic nevi']

answer: @entity75 :: (MESH:D001927,Disease) :: ['melanocytic lesions']


abstract: PURPOSE: To analyze the treatment plans of breast irradiation performed with two tangential beams, to discuss the importance of dose prescription, and to estimate the differences in delivered dose due to various dose prescription methods. MATERIAL AND METHODS: A survey was performed between the Hungarian radiotherapy centers in order to compare the dose prescription methods. Then, treatment plans of 125 @entity0 @entity1 treated in our department were evaluated. The irradiations were performed with @entity1953 unit, and with 6 and 9 MV photon beams of linear accelerators. The dose distributions were normalized to izocenter, then dose values in five points in central plane; local medial, lateral and central maximums (D(med), D(lat) and D(cent)); volumetric maximum and its location were determined. To characterize the dose to lung and to heart at left-sided @entity5 the @entity358 ( @entity358 ) and @entity299 ( @entity299 ) were used. Based on the results, estimation was made to assess the differences between delivered dose due to various dose prescriptions applied at the institutions. RESULTS: Four types of dose prescription are currently used in our country, and most frequently the isocenter is selected as a reference point. In the central plane the calculated dose in all but one points differed only a little from the dose to isocenter. The mean D(med), D(lat) and D(cent) were 107%, 107% and 101%, respectively. The volumetric maximum was on average 13% higher than the dose to isocenter. Regarding the beam qualities, this value was 16%, 13% and 11% for @entity1953 unit, 6 MV and 9 MV photon beams, respectively. The mean @entity358 and @entity299 were 1.9 and 0.8 cm, respectively. The difference between delivered doses at the institutions was 6% on average, but in extreme cases it can be as high as 20%. CONCLUSIONS: Three-dimensional treatment planning and plan evaluation are recommended at breast irradiation, especially for large breasts. Since the various dose prescriptions may result in significant differences in the delivered doses, use of a standard dose prescription protocol is recommended.

title: [Dosimetric assessment of external treatment plans for XXXX : the significance of dose prescription selection].

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['CLD', 'central lung distance']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['maximum heart distance', 'MHD']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: OBJECTIVE: The aim of this study is to document perioperative results and mid-term oncologic outcomes of @entity302 ( @entity302 ) colectomy compared to conventional laparoscopic (CL) colectomy. BACKGROUND: @entity302 surgery is an advance in minimally invasive operative techniques and is widely accepted for various types of surgery. METHODS: We prospectively collected data from 767 @entity1 who underwent radical colectomy (250 @entity302 colectomy and 517 CL colectomy) between 2010 and 2011 due to primary @entity694 and retrospectively analyzed these @entity1 with propensity score matching. RESULTS: Before matching, @entity1 with CL surgery had a significantly higher percentage of comorbidities (49.2% vs 57.8%, P = 0.024). Tumor location significantly differed between 2 groups: @entity302 surgery was performed more frequently in @entity1 with right @entity694 . After propensity score matching, each group included 239 @entity1 , and there was no difference between the @entity302 and CL surgery groups. Estimated @entity190 was more in the @entity1 with @entity302 colectomy, but the rate itself of intraoperative complications was not statistically different (P = 0.662). The median follow-up period was 37 months. There were 20 recurrences in the @entity302 surgery group (8.4%), including 3 locoregional recurrences and 18 (7.5%) in the CL surgery group. Disease-free survival at 48 months did not differ significantly between the @entity302 and CL surgery groups (89.8% vs 89.9%, P = 0.548). CONCLUSIONS: @entity302 colectomy for @entity694 shows probably higher, but an acceptable complication rate and can provide resection and oncologic outcomes equal to those of CL colectomy.

title: Oncologic Outcomes of Single-incision Laparoscopic Surgery Compared With Conventional Laparoscopy for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colon cancer']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['SIL', 'single-incision laparoscopic']

answer: @entity694 :: (MESH:D003110,Disease) :: ['Colon Cancer']


abstract: To determine how arteriolar dilation improves cardiac performance in @entity337 , we evaluated the acute effects of @entity2514 in 10 @entity1 with chronic severe @entity337 . Control measurements of intracardiac and intravascular pressures, cardiac output and left ventricular volumes were obtained at cardiac catheterization. @entity2514 , 0.3 mg/kg i.v. (maximal dose 20 mg), was administered and all measurements were repeated 30 minutes later. A reduction in systemic vascular resistance from 1264 to 710 dyn-sec-cm-5 was associated with significant increases in forward cardiac index (2.9 to 5.1 l/min/m2) and @entity64 volume index (37 to 55 ml/m2). Left ventricular end-diastolic pressure was reduced from 19 to 12 mm Hg. There was a significant reduction in mean arterial pressure (88 to 83 mm Hg) and a significant increase in heart rate (81 to 94 beats/min). Regurgitant @entity64 volume was reduced by more than 10 ml/m2 in seven @entity1 and for the group was significantly reduced, from 65 to 53 ml/m2. Regurgitant fraction was reduced in all @entity1 ; the overall reduction from 0.64 to 0.48 was highly significant. Ejection fraction increased more than 0.10 in four @entity1 , by 0.08 in an additional @entity1 and for the group increased significantly from 0.50 to 0.57. Left ventricular end-diastolic volume decreased by more than 25 ml/m2 in four @entity1 , by 19 ml/m2 in an additional @entity1 and was decreased significantly, from 208 to 190 ml/m2, for the group. Arteriolar dilators improve cardiac performance in @entity337 by reducing the amount of @entity337 and, in some @entity1 , by substantially improving systolic pump fraction. These data suggest a role for arteriolar dilators in the management of selected @entity1 with @entity337 .

title: Mechanism for improved cardiac performance with arteriolar dilators in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity2514 :: ('MESH:D006830', 'Chemical') :: ['hydralazine', 'Hydralazine']

entities_list: @entity337 :: ('MESH:D001022', 'Disease') :: ['aortic regurgitation', 'aortic insufficiency']

answer: @entity337 :: (MESH:D001022,Disease) :: ['aortic insufficiency']


abstract: @entity66 such as @entity2783 , @entity195 , @entity1579 , and the serpinopathies are all caused by structural rearrangements within a protein that transform it into a pathological species. These diseases are typified by the Z variant of alpha(1)-antitrypsin ( @entity26180 ), which causes the retention of protein within hepatocytes as inclusion bodies that are associated with @entity99 and @entity82 . The inclusion bodies result from the Z mutation perturbing the conformation of the protein, which facilitates a sequential interaction between the reactive center loop of one molecule and beta-sheet A of a second. Therapies to prevent @entity409 must block this reactive loop-beta-sheet polymerization without interfering with other proteins of similar tertiary structure. We have used reactive loop peptides to explore the differences between the pathogenic Z and normal M alpha(1)-antitrypsin. The results show that the reactive loop is likely to be partially inserted into beta-sheet A in Z alpha(1)-antitrypsin. This conformational difference from M alpha(1)-antitrypsin was exploited with a 6-mer reactive loop peptide (FLEAIG) that selectively and stably bound Z alpha(1)-antitrypsin. The importance of this finding is that the peptide prevented the polymerization of Z alpha(1)-antitrypsin and did not significantly anneal to other proteins (such as @entity5582 , @entity58553 ) with a similar tertiary structure. These findings provide a lead compound for the development of small molecule inhibitors that can be used to treat @entity1 with Z alpha(1)-antitrypsin deficiency. Furthermore they demonstrate how a conformational disease process can be selectively inhibited with a small peptide.

title: 6-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerization. Implications for the prevention of Z alpha(1)-antitrypsin-related XXXX .

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['Conformational diseases']

entities_list: @entity2783 :: ('MESH:D000686', 'Disease') :: ['amyloidosis']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver disease']

entities_list: @entity1579 :: ('MESH:D017096', 'Disease') :: ['prion diseases']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ["Alzheimer's disease"]

entities_list: @entity58553 :: ('12;5054', 'Gene') :: ['alpha(1)-antichymotrypsin, and plasminogen activator inhibitor-1']

entities_list: @entity99 :: ('MESH:D056486', 'Disease') :: ['neonatal hepatitis']

answer: @entity82 :: (MESH:D005355,Disease) :: ['cirrhosis']


abstract: BACKGROUND: One of the major challenges to total knee arthroplasty (TKA) is @entity158 control. Effective analgesia is capital in fast-track surgery programs to allow @entity1 's early functional outcomes. OBJECTIVES: Compare length of stay (LOS) short-term @entity158 control, and @entity1 ' satisfaction at 1 month between @entity1337 ( @entity1337 ) combined with @entity2096 ( @entity2096 ) and @entity2096 only in @entity1 undergoing TKA. @entity1 AND METHODS: Two hundred and fifty-four @entity1 were included in a randomized prospective study and distributed in two groups. The first group received an intraoperative @entity1337 (150 mL mixture of @entity1342 2.0 mg/mL + @entity6058 30 mg + @entity1425 10  g/mL) combined to an @entity2096 . The control group had only an @entity2096 . Demographical data and visual analog scale (VAS) score were obtained preoperatively, at 36 h after surgery and at the 15-day follow-up. @entity1 ' satisfaction at 1 month was also evaluated. Statistical analysis data was performed. RESULTS: No differences in demographical data and preoperative VAS score were observed between both groups. @entity1337 group had a lower VAS score at 36 h after surgery (1.34    1.31 vs. 3.68    1.932 in the control group, p = 0.00), but these differences were not maintained at the 15-day follow-up (4.51    1.889 vs. 4.11    1.940 in the control group, p > 0.05). LOS and @entity1 ' satisfaction were comparable between groups. @entity1 with @entity1337 had no additional complications. CONCLUSIONS: @entity1337 is a safe adjuvant to @entity2096 to reduce perioperative @entity158 during the first 36 h after TKA. Its effects wean with time, but do cover the first crucial hours of rehabilitation in a fast-track program. @entity1337 seems don't modify postoperative course nor @entity1 's satisfaction at short-term follow-up. The final impact of @entity1337 on surgical outcome is still to be determined.

title: Can XXXX increase satisfaction in postoperative short-term @entity158 control in total knee arthroplasty?

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS']

entities_list: @entity1425 :: ('MESH:D004837', 'Chemical') :: ['adrenaline']

entities_list: @entity1337 :: ('MESH:D000699', 'Disease') :: ['local infiltration analgesia', 'LIA']

entities_list: @entity1342 :: ('MESH:C037663', 'Chemical') :: ['ropivacaine']

entities_list: @entity6058 :: ('MESH:D020910', 'Chemical') :: ['ketorolac']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'optimal pain']

entities_list: @entity2096 :: ('MESH:D020428', 'Disease') :: ['femoral nerve block', 'FNB']

answer: @entity1337 :: (MESH:D000699,Disease) :: ['local infiltration analgesia']


abstract: OBJECTIVE: To determine the changes in body composition from 3 to 7 years of age in @entity1 undergoing adiposity rebound (AR) at different ages. METHODS: Body composition was measured bi-annually by bioelectrical impedance in 229 @entity1 from a birth cohort. Age at AR was calculated from changes in weight and height velocity over time. Early AR was defined as < 6.1 years ( @entity1 ) and < 5.6 years ( @entity1 ). Differences in fat mass (FM) and @entity1386 ( @entity1386 ) and the velocity of change in these measures were calculated between early and late rebounders. Physical activity (accelerometry), time in sedentary activity, birth factors, and parental weight were compared. RESULTS: @entity1 with early and late AR did not differ in body composition at 3 years of age, except for greater @entity1386 in @entity1 (by 0.8 kg, P = 0.022). In both sexes, change in body mass index (BMI) was significantly higher in early compared with late AR, and was entirely due to differences in the rate of @entity1017 , rather than any discrepancy in height velocity. This weight differential is predominantly due to increased deposition of FM in @entity1 and @entity1386 in @entity1 . However, in both sexes, @entity1 with early rebound have significantly greater increases in FM velocity from 5 years of age. Few differences in any environmental influences were observed. CONCLUSIONS: Variation in BMI associated with the timing of AR is due to differences in weight rather than height, and sex differences in the relative contribution of FM and @entity1386 to this additional @entity1017 are apparent.

title: Changes in fat mass and XXXX during the adiposity rebound: FLAME study.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Children', 'girls', 'boys']

entities_list: @entity1017 :: ('MESH:D015430', 'Disease') :: ['weight gain']

entities_list: @entity1386 :: ('MESH:D018205', 'Disease') :: ['FFM', 'fat-free mass']

answer: @entity1386 :: (MESH:D018205,Disease) :: ['fat-free mass']


abstract: UNASSIGNED: @entity8185 ( @entity4601 ) is a promising anti- @entity5 compound capable of inhibiting proliferation and inducing apoptosis of various @entity5 cells, including @entity14 . However, the molecular mechanisms have not been well understood. This study aimed to explore the underlying mechanism of @entity4601 -induced apoptosis in HCT-116 cells. Cell counting kit-8 assay and flow cytometry analysis confirmed that @entity4601 inhibited proliferation, arrested cell cycle at G0/G1 phase, and enhanced apoptosis in HCT-116 cells. @entity3576 /AM-stained flow cytometry assay revealed that the intracellular @entity141 concentration of HCT-116 cells was increased significantly after @entity4601 treatment. Meanwhile, the activity of sarco/endoplasmic reticulum @entity460 ATPase (SERCA) was appeared to be reduced in a dose-dependent manner. We further detected the upregulated expression of CAAT/enhancer binding protein homologous protein ( @entity3726 ) in @entity4601 -treated HCT-116 cells. Conversely, silencing @entity3726 resulted in a decrease of @entity4601 -induced apoptosis. In addition, the expression of @entity589 in cytoplasm was elevated significantly along with the sharply decline of @entity588 expression in @entity4601 -treated HCT-116 cells. Moreover, the distributions of Bid on mitochondria were increased, accompanied by the activation of @entity522 in the presence of @entity4601 . Overall, our data indicated that @entity4601 triggered endoplasmic reticulum (ER) stress through inhibiting SERCA activity to release intracellular @entity141 from ER, the upregulated expression of @entity3726 activated mitochondrial apoptosis pathway to induce apoptosis of HCT-116 cells. Therefore, our findings provide a theoretical foundation for @entity4601 as a potential candidate in treatment of @entity14 .

title: XXXX -Induced Apoptosis is Associated with Inhibition of Sarco/Endoplasmic Reticulum @entity460 ATPase Activity in @entity14 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity8185 :: ('MESH:C039060', 'Chemical') :: ['Dihydroartemisinin']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

answer: @entity8185 :: (MESH:C039060,Chemical) :: ['Dihydroartemisinin']


abstract: In this study the use of the polymerase chain reaction (PCR) to detect monoclonality in B-cell lymphoid proliferations in archival @entity406 -fixed paraffin-embedded tissue was assessed. Using consensus primers against the framework 3 (FR 3) region of the @entity7513 ( @entity7513 ), PCR analysis was performed on 29 low grade @entity1892 . Cases of @entity706 served as polyclonal controls. Sequenced cases of @entity981 served as positive controls. In the @entity706 , monoclonality could be demonstrated in 18 of 29 (62%) cases. Only five of 11 (45%) follicle centre cell @entity706 were positive by this method whilst the success rate for the remainder was 13 of 18 (72%). None of the polyclonal controls gave false positive results although occasional non-specific dominant bands were present which disappeared on repeating the experiments. These results show that this method will identify monoclonality in 62% of low grade @entity1892 in archival material. The success rate is increased to 72% if follicle centre cell @entity706 are excluded. Thus, this method is a useful adjunctive test to aid diagnosis in lymphoid infiltrates when standard morphology and immunohistochemistry are equivocal.

title: The use of the polymerase chain reaction in the diagnosis of XXXX from @entity406 -fixed paraffin-embedded tissue.

entities_list: @entity981 :: ('MESH:D054198', 'Disease') :: ['acute lymphoblastic leukaemia']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['benign lymphoid hyperplasia', 'lymphomas']

entities_list: @entity406 :: ('MESH:D005557', 'Chemical') :: ['formalin']

entities_list: @entity1892 :: ('MESH:D016393', 'Disease') :: ["B-cell non-Hodgkin's lymphomas"]

entities_list: @entity7513 :: ('3492', 'Gene') :: ['immunoglobulin heavy chain gene', 'IgH']

answer: @entity1892 :: (MESH:D016393,Disease) :: ['B-cell lymphomas']


abstract: Cytoplasmic granules from activated natural killer (NK) and cytotoxic T lymphocytes (CTL) contain a pore-forming protein, perforin, and several homologous @entity563 proteinases called granzymes. Expression of these proteins correlates with the cytolytic potential of cytotoxic lymphocytes. Using a panel of MoAbs specific for @entity1 @entity43642 , respectively, expression of these proteinases in non-pathological lymphoid tissue and peripheral blood lymphocyte (PBL) subpopulations was investigated. Using immunohistochemistry and double stainings, the phenotype of granzyme-expressing cells in lymphoid tissue was investigated. Granzyme-positive cells were detected in all lymphoid tissues tested. No large differences in the number and distribution between @entity24570 - and @entity10807 -positive cells were observed. The highest number of positive cells was located in the red pulp of the spleen. Significant numbers were detected in tonsil, lymph nodes, liver and thymus. Low numbers were present in the lamina propria of non-inflamed stomach, small intestine and colon. Phenotypic analysis and cell sorting showed that most of the granzyme-positive cells in lymphoid tissue and PBL consisted of CD3- @entity4071 + @entity2940 + lymphocytes. Hardly any granzyme-positive CD3+ @entity405 + CTL were present in peripheral blood. The synthesis of @entity24570 as well as B by both CD3+ @entity4071 + @entity2940 + and CD3+ @entity405 + cells in peripheral blood was increased upon @entity1199 stimulation. These results indicate that in normal lymphoid tissue the predominant cytolytic cell population is formed by the NK cells, and activated CTL are rare.

title: Localization and identification of @entity43642 -expressing cells in normal XXXX lymphoid tissue and peripheral blood.

entities_list: @entity563 :: ('CHEBI:17822', 'Chemical') :: ['serine']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: The bad prognosis of primary @entity6887 ( @entity6888 ), with 5-year overall survival rates of only 35%, is particularly ascribed to lymphogenous metastasis. Yet, we know very little on the pathophysiologic factors on which this lymphogenous metastasis is based. The present study, therefore, aims at evaluating the influence of @entity5 progression and @entity5 -cell anaplasia on lymphogenous metastasis in @entity6888 . We studied 41 cases of @entity6888 , who had been subjected to radical lymphadenectomy during primary operation in a retrospective analysis. Staging was done by International Federation of Gynecology and Obstetrics-classification. Histologic grading and nuclear DNA-content (DNA-index) were used for evaluating @entity5 -cell anaplasia. Histologic grading discriminated between highly differentiated (G1), moderately dedifferentiated (G2), and @entity5 . According to their DNA-indices, @entity5 were separated into three groups: DNA-index < or =1.1 (euploid cases), DNA-indices between 1.1 and 2.0 (cases of intermediate ploidy), and DNA-index >2.0 (aneuploid cases). The overall incidence of lymph node @entity3 was 43.9%. There was no correlation between histologic grading and DNA-index (P=0.98). Lymphogenous metastasis set in after the @entity5 had transgressed the tube (intra-abdominal stage II). Further @entity5 progression (including omentum, liver, or peritoneum) significantly increases the incidence of lymph node @entity3 (P=0.02). There was only a single G1- @entity5 that had already disseminated into the lymph, all other cases of lymph node @entity3 were found in G2- or G3- @entity5 . DNA-index and the extent of lymphogenous @entity3 were not found to be correlated (P=0.74). CONCLUSIONS: The extent of lymphogenous @entity3 in @entity6888 depends above all on @entity5 progression. This fact has clinical consequences as the indication for lymphadenectomy can be obtained directly during operation. The results of histologic grading are of no impact on the surgical proceedings; the determination of DNA-ploidy is negligible.

title: Tumor progression, histologic grading and DNA-ploidy as predictive factors of lymphogenous metastasis in primary XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['intra-abdominal tumor', 'tumor', 'dedifferentiated (G3) tumors', 'tumors']

entities_list: @entity6887 :: ('MESH:D005185', 'Disease') :: ['carcinoma of the Fallopian tube']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

answer: @entity6887 :: (MESH:D005185,Disease) :: ['carcinoma of the Fallopian tube']


abstract: Among 11,821 cases of @entity418 treated in a 32 year period, 7 were found to be associated with @entity1318 (0.059%). Five cases were proved by biopsy or cytology and 2 were diagnosed by esophagograms. There were 4 @entity1 and 3 @entity1 . The age ranged from 30-54 years with a median of 38. The age was younger than that of @entity418 unassociated with @entity1318 . Duration of @entity1318 was from 7 to 20 years. Three @entity1 died within 1 year and 1 died 17 months after diagnosis. Three were lost to follow-up. The presenting symptoms were aggravating @entity1282 in 4; and hoarseness, @entity1353 and bloody regurgitation in the other two. @entity1 with @entity1318 should be treated energetically in the early stage. Double contrast esophagography and esophagoscopy should be done carefully during the followup. Preparation of the esophagus is most important when performing the X-ray examination of the esophagus.

title: [Association of @entity418 with XXXX --report on 7 cases].

entities_list: @entity1318 :: ('MESH:D004931', 'Disease') :: ['achalasia']

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'men']

entities_list: @entity418 :: ('MESH:D004938', 'Disease') :: ['esophageal carcinoma']

entities_list: @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia']

answer: @entity1318 :: (MESH:D004931,Disease) :: ['achalasia']


abstract: BACKGROUND: @entity11011 @entity6674 is a specific neutrophil elastase inhibitor effective in @entity647 ( @entity647 ) associated with @entity1850 . @entity63 reperfusion injury (IRI) induced by supravisceral aortic clamping is associated with an excessive systemic inflammatory response, resulting in remote organ damage, including @entity647 . In this study, we investigated whether @entity11011 can attenuate neutrophil sequestration in the lung, alleviate @entity647 , and improve survival in a @entity35 bowel IRI model. METHODS: Adult male @entity35 underwent bowel IRI induced by supravisceral aortic clamping and were randomly assigned to receive @entity11011 or saline (control) and monitored for survival. We randomly assigned other @entity35 to undergo laparotomy alone (sham operation), IRI alone, or IRI and @entity11011 treatment. We evaluated blood samples for organ function, cytokine levels, and neutrophil elastase activity after reperfusion. Organs were analyzed histologically. We also determined @entity651 in another set of @entity35 . RESULTS: Bowel IRI induced a significant increase in serum variables indicative of organ function, cytokine concentrations, neutrophil elastase activity, and lung permeability and @entity4 , which reflected the presence of both @entity1850 and compensatory anti- @entity32 . Treatment with @entity11011 significantly improved survival rate, lung permeability and @entity4 , and significantly decreased levels of @entity1011 , @entity568 , @entity13358 , and neutrophil elastase activity. Histological studies showed that @entity11011 -treated @entity35 had less bowel IRI-induced @entity409 than controls. CONCLUSION: In a @entity35 model, administration of @entity11011 attenuated the effects of bowel IRI induced by supravisceral aortic clamping, and improved the survival rate.

title: Neutrophil elastase inhibitor improves survival rate after @entity63 reperfusion injury caused by supravisceral aortic clamping in XXXX .

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammatory response syndrome']

entities_list: @entity35 :: ('10116', 'Species') :: ['rat', 'Sprague-Dawley rats', 'rats']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['Bowel ischemia']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['damage to lung and liver tissue']

entities_list: @entity651 :: ('MESH:D055370', 'Disease') :: ['lung injury']

entities_list: @entity6674 :: ('CHEBI:32145', 'Chemical') :: ['sodium hydrate']

entities_list: @entity1850 :: ('MESH:D018746', 'Disease') :: ['systemic inflammatory response syndrome']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity11011 :: ('MESH:C069195', 'Chemical') :: ['Sivelestat', 'sivelestat']

entities_list: @entity647 :: ('MESH:D055371', 'Disease') :: ['acute lung injury', 'ALI']

answer: @entity35 :: (10116,Species) :: ['rats']


abstract: In fetuses and neonates @entity99 are relatively common lesions and may be life-threatening. Conditions previously associated with these @entity1410 include @entity130 , @entity1003 , @entity519 , @entity295 , pneumothorax, @entity66 , and @entity5028 . In this study of 755 perinatal autopsies, @entity99 were found in 52 (6.9%) cases, including 31 stillborn fetuses and 21 liveborn @entity1 . The average body weight was 690 g. A comparison group consisted of 52 temporally proximal autopsies of fetuses and neonates without @entity1410 . Body weights, gender, maternal age, and @entity2209 or postnatal survival were matched as closely as possible while evaluating the presence or absence of @entity295 , pneumothorax, @entity1779 , @entity130 , @entity1003 , @entity5028 , and @entity66 . @entity295 was associated with 62% of the cases with @entity99 and with 25% of the comparison group (P =.0001). Group B streptococcus infection was the most common cause of @entity295 , but many different organisms were isolated. @entity1779 were present in 35% of the cases with @entity1410 and in 14% of the comparison group (P =.0001). No other lesions or conditions were statistically different in the study group versus the comparison group. The delicacy of the hepatic capsule and its connections to the collagen along the sinusoids provide insight for the pathogenesis of @entity1410 in premature fetuses and neonates. We conclude that @entity295 is present in most perinatal cases of @entity99 and that such @entity1 also frequently have cerebral germinal matrix @entity548 . Each of these lesions is a greater hazard among very small premature fetuses or neonates than among older fetuses and neonates.

title: Hepatic subcapsular XXXX in fetuses and neonatal @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'infants']

entities_list: @entity295 :: ('MESH:D018805', 'Disease') :: ['sepsis', 'Sepsis']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['maternal diseases']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhages']

entities_list: @entity2209 :: ('MESH:D050497', 'Disease') :: ['stillbirth']

entities_list: @entity5028 :: ('MESH:D010922', 'Disease') :: ['placental lesions']

entities_list: @entity1003 :: ('MESH:D001778', 'Disease') :: ['coagulopathies', 'coagulopathy']

entities_list: @entity1410 :: ('MESH:D006406', 'Disease') :: ['hematomas']

entities_list: @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic subcapsular hematomas']

entities_list: @entity1779 :: ('MESH:D002543', 'Disease') :: ['cerebral germinal matrix hemorrhage', 'Cerebral germinal matrix hemorrhages']

answer: @entity1410 :: (MESH:D006406,Disease) :: ['hematomas']


abstract: PURPOSE: To evaluate the feasibility and safety of @entity2998 ( @entity2998 ) performed by a dedicated multidisciplinary team in a community hospital. METHODS: Forty-nine @entity1 (30 @entity1 ; mean age 74.3 +/- 7.4 years, range 51-88) with 14 symptomatic and 35 asymptomatic >50% carotid stenoses were enrolled into the study and treated with self-expanding stents without cerebral protection. The @entity1 were evaluated at 30 days for @entity204 , neurological sequelae, and length of stay. A contemporaneous group of 140 @entity1 (80 @entity1 ; mean age 72.3 +/- 7.7 years, range 43-89) undergoing carotid endarterectomy (CEA) was used for comparison of the outcome measures. Owing to crossover of failed @entity2998 @entity1 to the CEA group, the data were analyzed according to intention-to-treat and treatment-received. RESULTS: The only difference in baseline characteristics between the treatment and control groups was the greater frequency of bilateral disease in the CEA group (p=0.009). The @entity2998 procedures were successful in 47 (96.0%) @entity1 ; 2 access failures were converted to endarterectomy, and 1 access-site @entity2849 was treated surgically. There were no deaths or @entity583 in either group. In the @entity2998 group, there were no major and only 2 (4.1%) minor @entity64 compared to 4 (2.9%) major and 4 (2.9%) minor @entity64 in the CEA group (p>0.05). Median LOS was significantly lower in the @entity2998 group (p<0.0001). CONCLUSIONS: Careful case selection and multidisciplinary collaboration facilitate the safe performance of carotid stenting in a community setting with acceptable early results.

title: Unprotected XXXX compared to carotid endarterectomy in a community setting.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'men']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['strokes']

entities_list: @entity2998 :: ('MESH:D002340', 'Disease') :: ['carotid artery stenting', 'CAS']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarctions']

entities_list: @entity2849 :: ('MESH:D017541', 'Disease') :: ['pseudoaneurysm']

answer: @entity2998 :: (MESH:D002340,Disease) :: ['carotid artery stenting']


abstract: BACKGROUND AND AIM: The most effective schedule of @entity7080 inhibitor (PPI) administration and the optimal timing of endoscopy in acute peptic @entity1066 remain uncertain. The aim of this study was to determine the most efficient PPI regimen and optimal timing of endoscopy. METHODS:     Consecutive @entity1 with suspected @entity548 peptic ulcers were enrolled and randomized to receive either a standard regimen or a high-dose intensive intravenous regimen. Only @entity1 with @entity548 peptic ulcers diagnosed at initial endoscopy continued the study. High-risk @entity1 received endoscopic hemostasis. The primary outcome measure of recurrent @entity548 was compared between the two dosage regimens and between early and late endoscopy. Secondary outcome measures compared included need for endoscopic treatment, blood transfusion, hospital stay, surgery and mortality. RESULTS: A total of 875 @entity1 completed the study. Recurrent @entity548 occurred in 11.0% in the standard regimen group, statistically higher than that in the intensive regimen group (6.4%, P=0.02). Mean units of blood transfused and duration of hospital stay were also higher in the standard regimen group (P<0.001 for each compared to intensive regimen group). However, no significant differences were noted between the two groups in the need for endoscopic hemostasis, need for surgery, and mortality. Recurrence of @entity548 was similar between the early and late endoscopy groups. Units of blood transfused and length of hospital stay were both significantly reduced with early endoscopy. CONCLUSION: High-dose PPI infusion is more efficacious in reducing rebleeding rate, blood transfusion requirements and hospital stay. Early endoscopy is safe and more effective than late endoscopy.

title: Effect of intravenous @entity7080 inhibitor regimens and timing of endoscopy on clinical outcomes of peptic XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcer bleeding']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

answer: @entity1066 :: (MESH:D014456,Disease) :: ['ulcer bleeding']


abstract: BACKGROUND: Accurate response assessment is essential for evaluating new @entity5 treatments. We evaluated the impact of Response Evaluation Criteria in @entity5 (RECIST), World Health Organization (WHO) criteria and @entity5 shape on response assessment in @entity1 with metastatic @entity418 . @entity1 AND METHODS: In 19 @entity1 with metastatic @entity418 in a phase II trial of @entity10186 and @entity1311 , response was retrospectively assessed for 89 lesions with RECIST and WHO criteria on baseline and serial follow-up CT scans. The eccentricity factor (EF) was introduced for measuring the degree to which @entity5 shape diverges from a perfect sphere [EF = radical1-(LPD/ @entity601 )(2), where LPD is the largest perpendicular diameter and @entity601 is the maximal diameter]. RESULTS: The disagreement rate in best overall response categorization between RECIST (unidimensional) and WHO (bidimensional) criteria was 26.3%. Change in eccentricity was significantly greater (P < 0.01) for @entity1 with disagreement (mean 0.31, range 0-0.91). When the short axis was used for unidimensional lymph node measurement, disagreement between WHO and RECIST lessened. CONCLUSIONS: Response assessment by WHO and RECIST differs substantially. Greater change in eccentricity is associated with greater discordance between WHO and RECIST. The discordance between WHO and RECIST may impact on how effective a therapy is judged to be.

title: Measuring XXXX response and shape change on CT: @entity418 as a paradigm.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Solid Tumors', 'cancer']

entities_list: @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel']

entities_list: @entity418 :: ('MESH:D004938', 'Disease') :: ['esophageal cancer']

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumor']


abstract: Stress sensitization, whereby CA lowers tolerance to later stressors, has been proposed as a potential mechanism explaining the association between exposure to childhood adversities (CA) and @entity734 in adulthood. However, this mechanism remains untested. This paper begins to address this gap through exploring associations between CA exposure and stressful events in adulthood for predicting @entity734 . We used data drawn from @entity13831 of the U.S. National Epidemiological Survey of @entity167 and Related Conditions (n = 34,653) to explore whether the association between past-year stressful life events and the 12-month prevalence of disordered @entity835 , stimulant, and opiate use varied by the number of types of CA that an individual was exposed to. Past-year stressful life events were associated with an increased risk of @entity835 , stimulant, and opiate use disorders among @entity1 and @entity1 . Exposure to CA was associated with increased risk for disordered @entity835 use among @entity1 and @entity1 and opiate use among @entity1 only. Finally, we found significant associations between exposure to CA and past-year stressful life events in predicting disordered drug use, but only for @entity1 in relation to disordered stimulant and opiate use. Findings are suggestive of possible stress sensitization effects in predicting disordered stimulant and opiate use among @entity1 . Implications of these findings for the prevention and treatment of @entity734 and for future research are discussed. (PsycINFO Database Record (c) 2014 APA, all rights reserved).

title: Associations between childhood adversity, adult stressful life events, and past-year @entity734 in the National Epidemiological Study of XXXX and Related Conditions (NESARC).

entities_list: @entity167 :: ('CHEBI:16236', 'Chemical') :: ['Alcohol']

entities_list: @entity835 :: ('MESH:D002189', 'Disease') :: ['cannabis']

entities_list: @entity734 :: ('MESH:D019966', 'Disease') :: ['drug use disorders']

answer: @entity167 :: (CHEBI:16236,Chemical) :: ['Alcohol']


abstract: BACKGROUND: The number of @entity1 diagnosed with @entity263 is increasing and internationally there are high incidence rates. It is important that nurses and healthcare professionals are enabled to provide appropriate care to those @entity1 affected by @entity263 and their families. Despite this need, there is recognition that many professionals feel ill prepared and lack knowledge in a number of areas. This paper presents the development of a Virtual @entity1 (VP) online resource to support practitioner learning. AIM: To develop five online VP simulation scenarios to meet the learning needs of nurses and health-care professionals caring for @entity1 with @entity263 . METHOD: Topic areas for the VPs were taken from previous work exploring the needs of health care professionals working with @entity1 with @entity263 . An initial scoping exercise involving nursing practitioners, students and a @entity263 charity confirmed the focus of the case study scenarios. Service users and specialist practitioners reviewed an outline of each case study to ensure fidelity of the simulations scenarios. Cases were entered into UChoose, a web based interactive VP player and authoring tool. The final case studies were reviewed by a sample of both registered and non-registered nurses and nursing students. RESULTS: The majority of respondents reported an increase in knowledge and suggested that they would recommend the resource to others. A number of positive aspects of the resource were highlighted. Respondents also commented about areas of weakness, a number of which have been addressed subsequently. CONCLUSIONS: The VP case studies provided an opportunity to develop knowledge and confidence in caring for @entity1 with @entity263 . The mode of delivery and the content was acceptable for less experienced and knowledgeable staff.

title: Virtual XXXX : Development in cancer nursing education.

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: During recent years, the national policy of the United Kingdom has increasingly recognized the central place of general practitioners (GPs) in the care of @entity5 @entity1 , from screening and early diagnosis through to palliative care and bereavement. There are, however, continuing reports of poor control of @entity158 and other symptoms in the community. To investigate general practitioners' prescribing habits and knowledge of some key @entity158 control issues in advanced @entity5 , a postal questionnaire surveyed a random sample of 450 East Anglian GPs. The response rate was 73.3%. Most respondents were familiar with the modern management of @entity5 , including the World Health Organization approach, the use of oral opioids, and the management of @entity158 . There was less awareness of the drug options available for more uncommon situations, especially the dose conversion of oral @entity1286 to subcutaneous @entity4521 and drugs that may be used in syringe drivers. GPs in the UK are familiar with the management of the more common @entity158 control problems. However, it is not appropriate to expect GPs to know the details of management of more unusual @entity5 problems. Specialist clinicians need to make themselves readily available to advise their generalist colleagues. The educational implications for GPs are discussed.

title: Controlling XXXX in primary care: the prescribing habits and knowledge base of general practitioners.

entities_list: @entity4521 :: ('MESH:D003932', 'Chemical') :: ['diamorphine']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'cancer pain']

entities_list: @entity1286 :: ('MESH:D009020', 'Chemical') :: ['morphine']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['bone pain', 'pain']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer pain']


abstract: @entity4243 ( @entity4243 ) type I was diagnosed in an 18-year-old @entity1 on the basis of marked skin hyperextensibility with generalized @entity12458 , pigmented paper-tissue scars, and a pronounced tendency to @entity2981 . Her father and one of her sisters showed a similar phenotype. Her mother was normal. Light microscopy of skin biopsies showed large, irregular collagen fibres in the father and daughter, with normal findings in the mother. Electron microscopy of the skin sections revealed a variation in diameter and shape of the collagen fibrils as well as slight dilatation of the rough endoplasmic reticulum of fibroblasts in father and daughter, but normal findings in the mother. Cultured fibroblasts did not show these changes. Measurements of collagen synthesis by fibroblast cultures showed that type III collagen levels were reduced to 50% of normal in the father and daughter, and were normal in the mother. The alpha I (III) proteins had a normal molecular weight, determined by @entity214 -PAGE electrophoresis. The phenotypes and biochemical results in the family members tested were compatible with autosomal dominant transmission. To our knowledge, this is the first report of a @entity1413 in @entity15354 . The findings in this family, especially the pronounced @entity2981 tendency, illustrate the heterogeneity within type I @entity4243 .

title: XXXX : a clinical and ultrastructural study of a family with reduced amounts of collagen type III.

entities_list: @entity15354 :: ('MESH:C536194', 'Disease') :: ['Ehlers-Danlos syndrome type I']

entities_list: @entity4243 :: ('MESH:D004535', 'Disease') :: ['Ehlers-Danlos syndrome', 'EDS']

entities_list: @entity12458 :: ('MESH:D007594', 'Disease') :: ['loose-jointedness']

entities_list: @entity1413 :: ('MESH:D003095', 'Disease') :: ['type III collagen deficiency']

answer: @entity15354 :: (MESH:C536194,Disease) :: ['Ehlers-Danlos syndrome type I']